GMAB (Genmab AS) Change In Inventory : $0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Genmab AS Change In Inventory?

Genmab AS's change in inventory for the quarter that ended in Dec. 2024 was $0 Mil. It means Genmab AS's inventory stayed the same from Sep. 2024 to Dec. 2024 .

Genmab AS's change in inventory for the fiscal year that ended in Dec. 2024 was $-1 Mil. It means Genmab AS's inventory increased by $1 Mil from Dec. 2023 to Dec. 2024 .

Genmab AS's Total Inventories for the quarter that ended in Dec. 2024 was $9 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Genmab AS's Days Inventory for the quarter that ended in Dec. 2024 was 18.58.

Inventory Turnover measures how fast the company turns over its inventory within a year. Genmab AS's Inventory Turnover for the quarter that ended in Dec. 2024 was 4.91.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genmab AS's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.01.

Genmab AS Change In Inventory Historical Data

The historical data trend for Genmab AS's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Change In Inventory Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

-8.34

-0.70

Genmab AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Genmab AS Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Genmab AS (NAS:GMAB) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genmab AS's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	9.637	/	47.317	*	365 / 4
	=	18.58

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genmab AS's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	47.317	/	9.637
	=	4.91

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genmab AS's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	9.637	/	904.368
	=	0.01

Genmab AS Change In Inventory Related Terms

Thank you for viewing the detailed overview of Genmab AS's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:Mexico GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GE91:Germany GE9:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.